Mirum Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $154.43, Implies 77% Upside

What happened

Estimates from 14 analysts put Mirum Pharmaceuticals’ average 12-month share-price target at $154.43, up from $153.43. Based on the November 3 closing price, that target suggests about 77% potential upside. The consensus rating remains Buy among 15 analysts: 15 Buys, no Holds and no Sells.

Confirmed

Global impact / market context

The higher target is an analyst forecast, not a guaranteed return. If investors buy shares in response to the Buy consensus, demand could support the share price; if expectations disappoint, the target’s implied upside may not be realized, leaving investors exposed to a price decline.

Analyst inference

Analyst forecasts range from $118 to $200 per share, a wide spread despite all 15 covering analysts rating the stock Buy. That contrast suggests agreement on the direction of the recommendation but differing views on the share value analysts expect.

Confirmed

What to watch

1. Compare later average targets with $154.43 and note whether estimates rise or fall; changes can influence investor expectations and buying or selling interest in Mirum shares. Analyst inference
2. Watch for shifts in Buy, Hold, or Sell ratings among the 15 covering analysts, since changing recommendations could alter investor demand and pressure the share price. Analyst inference
3. The article gives no operating results or reasons for the target increase, so seek evidence that business performance supports analysts’ expectations before treating the implied upside as achievable. Confirmed

Evidence

• Original source link unavailable